Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.30 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.30 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1946821 | 0.74 | ALDH1A1 (0.31) | ALDH1A1POLBMAPTHTTSMN1; SMN2 | |
| SCHEMBL819057 | 0.72 | — | — | |
| SCHEMBL6098447 | 0.70 | ALDH1A1 (0.31) | ALDH1A1POLBMAPTHTTSMN1; SMN2 | |
| SCHEMBL16341734 | 0.69 | — | — | |
| SCHEMBL16341690 | 0.69 | — | — | |
| SCHEMBL16341694 | 0.69 | — | — | |
| SCHEMBL16340855 | 0.69 | — | — | |
| SCHEMBL29010438 | 0.68 | ALDH1A1 (0.33) | ALDH1A1POLBMAPTHTTSMN1; SMN2 | |
| SCHEMBL1946829 | 0.68 | — | — | |
| SCHEMBL22188949 | 0.67 | ALDH1A1 (0.34) | ALDH1A1POLBMAPTHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2151446-B1 | Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand | RIMTEC CORP (JP) | 2016-04-13 | — | — | EP | disclosed |
| EP-2151445-B1 | Process for the preparation of bidentate Schiff base ruthenium catalysts containing a salicylaldimine-type ligand | RIMTEC CORP (JP) | 2015-02-18 | — | — | EP | disclosed |
| US-8338613-B2 | Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand | RIMTEC CORPORATION (JP) | 2012-12-25 | — | — | US | disclosed |
| US-20110137043-A1 | Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand | TELENE S.A.S. (FR) | 2011-06-09 | — | — | US | disclosed |
| US-20110065925-A1 | Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand | TELENE S.A.S. (FR) | 2011-03-17 | — | — | US | disclosed |
| EP-2151446-A1 | Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand | Telene SAS (FR) | 2010-02-10 | — | — | EP | disclosed |
| EP-2151445-A1 | Process for the preparation of bidentate Schiff base ruthenium cataysts containing a saliclyldimine-type ligand | Telene SAS (FR) | 2010-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110137043-A1 | Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand | SPR, LIG4, SUCLA2 | ALDH1A1 1371/4885POLB 800/4885MAPT 3633/4885 |
| US-20110065925-A1 | Process for the preparation of bidentate schiff base ruthenium catalysts containing a salicylaldimine-type ligand | SPR, LIG4, SUCLA2 | ALDH1A1 1371/4885POLB 800/4885MAPT 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.